Group One Trading’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Group One Trading’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.5K	Sell	300 -1,271	-81%	-$52K	﹤0.01%	6238
2025 Q4	$60.6K	Buy	+1,571	New	+$53.4K	﹤0.01%	5434

Other funds holding BBC

KCP

Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

MCM

Militia Capital Management Austin, Texas $454M AUM

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

APW

Aurora Private Wealth Rockaway, New Jersey $140M AUM

FTUS

Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Group One Trading's BBC Position: Q1 2026 in Review

Group One Trading reduced its Virtus Biotech Clinical Trials ETF (BBC) stake by 81% in Q1 2026, selling an estimated $52K and leaving 300 shares worth $12.5K. The position accounts for ﹤0.01% of the portfolio, ranked #6238.

Group One Trading first reported a position in BBC in Q4 2025 and has held it in 2 quarters since. The position peaked at $60.6K in Q4 2025. 20 funds tracked by Wall St. Rank hold BBC as of Q1 2026.

Group One Trading held 300 shares of Virtus Biotech Clinical Trials ETF worth $12.5K as of Q1 2026.
Group One Trading sold 1,271 Virtus Biotech Clinical Trials ETF shares in Q1 2026, an estimated $52K.
Virtus Biotech Clinical Trials ETF made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #6238 holding.
Group One Trading first reported a position in Virtus Biotech Clinical Trials ETF in Q4 2025 and has held it in 2 quarters since.
Group One Trading's Virtus Biotech Clinical Trials ETF position peaked at $60.6K in Q4 2025.
20 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.